The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Extended follow-up of glofitamab with polatuzumab in heavily pre-treated R/R LBCL, including HGBCL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents the results of the long-term follow-up of a study investigating the combination of glofitamab and polatuzumab vedotin in heavily pretreated patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (NCT03533283), including patients with high-grade B-cell lymphoma (HGBCL). Dr Hutchings highlights that the combination of therapy resulted in high overall and complete response rates (ORR and CR, respectively), and responses were durable, including in the difficult-to-treat patient population with HGBCL. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a combination study of immunotherapies in the space of relapsed/refractory B-cell lymphomas. We presented data from this study a couple of times, but these are really mature data with the full cohort of 129 patients with aggressive non-Hodgkin lymphomas, relapsed/refractory disease, the vast majority of those with two or more prior lines of treatment, but also with a small minority of patients with only one prior line of treatment, predominantly high-grade B-cell lymphoma patients...
This is a combination study of immunotherapies in the space of relapsed/refractory B-cell lymphomas. We presented data from this study a couple of times, but these are really mature data with the full cohort of 129 patients with aggressive non-Hodgkin lymphomas, relapsed/refractory disease, the vast majority of those with two or more prior lines of treatment, but also with a small minority of patients with only one prior line of treatment, predominantly high-grade B-cell lymphoma patients. And actually this study enriched the population of high-grade B-cell lymphoma, typically a very difficult to treat population. So out of a total of 129 patients, forty-four patients, so roughly one-third of patients, had high-grade B-cell lymphomas.
We demonstrated before the very high overall and complete response rates we see with a combination of glofitamab and polatuzumab vedotin. So, glofitamab is a bispecific CD3/CD20 antibody. Polatuzumab vedotin is a well-known anti-CD79 ADC, which is approved already in first and second line treatment together with chemotherapy. But together, these two compounds result in very high overall response rates of beyond 80 percent, also in the subpopulation of high-grade B-cell lymphomas, and complete response rates higher than 60% and actually around 65-66% in the high grade B-cell lymphoma subpopulation.
And what about the durability? Well, it’s also quite good. So we see that with a median follow-up of more than two years, the durability of the complete responses is comfortably above 50%. So we have a progression-free survival for the whole group of patients building at around 40% at a very mature point in follow-up. So really promising results and particularly for the, like I said, very difficult to treat population of high-grade B-cell lymphomas.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Membership on an entity’s Board of Directors or advisory committees, Research Funding; BMS/Celgene: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genmab: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen/J&J: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Research Funding.
